Skip to main content

Toxoplasma gondii – gegenwärtige Arzneimittel und zukünftige Impfstoffe gegen eine unterschätzte Protozoonose

Toxoplasma gondii—Current drugs and future vaccines against an underestimated protozoan infection


Toxoplasma gondii ist ein weltweit auftretender parasitärer Einzeller der Apicomplexa und somit ein naher Verwandter des Malariaerregers Plasmodium. Da Tgondii zum einen jede warmblütige Wirbeltierart als Zwischenwirt befällt und zum anderen eine weltweit sehr hohe Prävalenz aufweist, gehört die Toxoplasmose zu den international wichtigsten Lebensmittelerkrankungen. Mögliche Impfstoffe (humane wie veterinäre) spielen bei der Kontrolle dieser Erkrankung eine entscheidende Rolle.


Toxoplasma gondii is a unicellular organism of the Apicomplexa that occurs worldwide and is therefore a close relative of the malaria pathogen Plasmodium. As Tgondii infests every warm-blooded vertebrate species as an intermediate host and has a very high prevalence worldwide, toxoplasmosis is one of the most important international foodborne diseases. Potential vaccines (human as well as veterinary) play a crucial role in controlling this disease.

This is a preview of subscription content, access via your institution.

Abb. 1
Abb. 2


  1. 1.

    Adeyemi OS, Murata Y, Sugi T, Kato K (2017) Inorganic nanoparticles kill Toxoplasma gondii via changes in redox status and mitochondrial membrane potential. Int J Nanomed 12:1647–1661

    Article  Google Scholar 

  2. 2.

    Ammar S, Purple K, Gerhold R (2020) Toxoplasma gondii prevalence in hunter-killed mourning doves (Zenaida macroura) and rock pigeons (Columba livia) from East Tennessee, USA. J Wildl Dis 56(2):479–481

    PubMed  Article  Google Scholar 

  3. 3.

    anses (2016) Toxoplasmose. Zugegriffen: 13. Juni 2021

  4. 4.

    Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9(4):308–324

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Attias M, Teixeira DE, Benchimol M, Vommaro RC, Crepaldi PH, De Souza W (2020) The life-cycle of Toxoplasma gondii reviewed using animations. Parasites Vectors 13:588

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Bai MJ, Wang JL, Elsheikha HM, Liang QL, Chen K, Nie LB, Zhu XQ (2018) Functional characterization of dense granule proteins in Toxoplasma gondii RH strain using CRISPR-Cas9 system. Front Cell Infect Microbiol 8:300

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  7. 7.

    Basavaraju A (2016) Toxoplasmosis in HIV infection: An overview. Trop Parasitol 6(2):129–135

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Borkens Y (2020) Ist eine Malaria-Impfung möglich? – Verschiedene Impfkandidaten und ihr Potenzial gegen Plasmodium-Parasiten. Med Monatsschr Pharm 43(8):317–321

    Google Scholar 

  9. 9.

    CDC’s Division of Parasitic Diseases and Malaria, DPDx (2020) Parasites—Toxoplasmosis (Toxoplasma infection): Biology. Zugegriffen: 19. Mai 2021

  10. 10.

    CDC’s Division of Parasitic Diseases and Malaria, DPDx (2018) Parasites—toxoplasmosis (Toxoplasma infection): epidemiology & risk factors.,have%20been%20infected%20with%20Toxoplasma. Zugegriffen: 25. Mai 2021

  11. 11.

    Ching XT, Fong MY, Lau YL (2017) Evaluation of the protective effect of deoxyribonucleic acid vaccines encoding granule antigen 2 and 5 against acute toxoplasmosis in BALB/c mice. Am J Trop Med Hyg 96:1441–1447

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Chu KB, Quan FS (2021) Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development. Vaccines 9:413

    PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, Foulon W, Semprini AE, Dunn DT (2000) Sources of Toxoplasma infection in pregnant women: European multi centre case-control study. European Research Network on congenital Toxoplasmosis. BMJ 15:142–147

    Article  Google Scholar 

  14. 14.

    Deutschlandfunk (2008) Medizin: Ein Malaria-Medikament hilft gegen Toxoplasmose. Zugegriffen: 23. Apr. 2021

  15. 15.

    Dimier-Poisson L, Carpentier R, N’Guyen TT, Dahmani F, Ducournau C, Berbeder D (2015) Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials 50:164–175

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Dubey JP (1984) Experimental toxoplasmosis in sheep fed Toxoplasma gondii oocysts. Int Goat Sheep Res 2:93–104

    Google Scholar 

  17. 17.

    Dubey JP, Urban JF Jr., Davis SW (1991) Protective immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii. Am J Vet Res 52:1

    Google Scholar 

  18. 18.

    Dubey JP (1998) Advances in the life cycle of Toxoplasma gondii. Int J Parasitol 28(7):1019–1024

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Roberts CW, Lanar DE, Reed S, Fox C, Carter D, Alexander J, Sette A, Sidney J, Lorenzi H, Begeman IJ, Burkhard P, McLeod R (2017) Protein nanovaccine confers robust immunity against Toxoplasma. NPJ Vaccines 2:24

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  20. 20.

    El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Reed S, Estes A, Estes A, Lykins J, Burkhard P, McLeod R (2020) Engineering and characterization of a novel self assembling protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Sci Rep 10:16984

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  21. 21.

    Flegr J (2013) How and why Toxoplasma makes us crazy. Trends Parasitol 29(4):156–163

    PubMed  Article  Google Scholar 

  22. 22.

    Flegr J, Prandota J, Sovičkova M, Israili ZH (2014) Toxoplasmosis—A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. Plos One 9(3):e90203

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  23. 23.

    Frenkel JK, Pfefferkorn ER, Smith DD, Fishback JL (1991) Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats. Am J Vet Res 52:759–763

    CAS  PubMed  Google Scholar 

  24. 24.

    Gibb DGA, Kakulas BA, Perret DH, Jenkyn DJ (1966) Toxoplasmosis in the rottnest quokka (Setonix brachyurus). Aust J Exp Biol Med Sci 44(6):665–672

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Global Health, Division of Parasitic Diseases and Malaria (2018) Parasites—Toxoplasmosis (Toxoplasma infection): Treatment. Zugegriffen: 20. Aug. 2021

  26. 26.

    Götze S, Reinhardt A, Geissner A, Azzouz N, Tsai YH, Kurucz R, Varón SD, Seeberger PH (2015) Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model. Glycobiology 25(9):984–991

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Ishtiaq F, Swain S, Kumar SS (2021) Anopheles stephensi (Asian Malaria Mosquito). Trends Parasitol.

    Article  PubMed  Google Scholar 

  28. 28.

    Jenner E (1799) History of the inoculation of the Cow-Pox: Further observations on the Variolæ Vaccinæ, or Cow-Pox. Med Phys J 1(4):313–318

  29. 29.

    Jenner E (1800) Dr. Jenner, on the Vaccine Inoculation. Med Phys J 3(16):502–503

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB (2001) Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 154(4):357–365

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31:58–83

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Lee DH, Kim AR, Lee SH, Quan FS (2016) Cross-protection induced by Toxoplasma gondii virus-like particle vaccine upon intraperitoneal route challenge. Acta Trop 164:77–83

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Lee DH, Lee SH, Kim AR, Quan FS (2016) Virus-like nanoparticle vaccine confers protection against Toxoplasma gondii. PLoS ONE 11:e161231

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  34. 34.

    Le Roux D, Djokic V, Morisse S, Chauvin C, Doré V, Lagrée AC, Voisin D, Villain Y, Grasset-Chevillot A, Boursin F, Su C, Perrot S, Vallée I, Seche E, Blaga R (2020) Toxoplasma gondii live attenuated strain in the feline host. Vaccine 38:1457–1466

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Li Y, Zhou H (2018) Moving towards improved vaccines for Toxoplasma gondii. Expert Opin Biol Ther 18:273–280

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Lung P, Yang J, Li Q (2020) Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale 12:5746–5763

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Maldonado YA, Read JS, Committee on infectious diseases (2017) Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics 139(2):e20163860

    PubMed  Article  Google Scholar 

  38. 38.

    Mandelbrot L, Kieffer F, Wallon M, Winer N, Massardier J, Picone O, Fuchs F, Benoist G, Garcia-Meric P, L’Ollivier C, Paris L, Piarroux R, Villena I, Peyron F (2021) Toxoplasmose pendant la grossesse: proposition actuelle de prise en charge pratique. Gynecol Obstet Fetil Senol.

    Article  Google Scholar 

  39. 39.

    Mateus-Pinilla NE, Hannon B, Weigel RM (2002) A computer simulation of the prevention of the transmission of Toxoplasma gondii on swine farms using a feline T. gondii vaccine. Prev Vet Med 55:17–36

    PubMed  Article  Google Scholar 

  40. 40.

    McDermott DH, Heusinkveld LE, Zein WM, Sen HN, Marquessen MM, Parta M, Rosenzweig SD, Fahle GA, Keller MD, Wiley HE, Murphy PM (2019) Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient [Version 2; peer review: 3 approved. F1000 Res 8:2.

    Article  Google Scholar 

  41. 41.

    Mineo JR, Kasper LH (1994) Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG‑1 (P30). Exp Parasitol 79(1):11–20

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Mohabati R, Babaie J, Amiri S, Talebzadeh M, Fard-Esfahani P, Darbouy M, Golkar M (2013) Expression and purification of recombinant ROP1 of Toxoplasma gondii in bacteria. Avicenna J Med Biotechnol 5(4):227–233

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363(9425):1965–1976

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R (2008) Novel Triazine JCP-2067‑B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis 2(3):e190

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  45. 45.

    Nicolle C, Manceaux L (1908) Sur une infection a corps de Leishman (ou organismes voisons) du gondi. C R Acad Sci 147:736

    Google Scholar 

  46. 46.

    Nicolle C, Manceaux L (1909) Sur un protozaire nouveau du gondi. C R Acad Sci 148:369

    Google Scholar 

  47. 47.

    Opsteegh M, Spano F, Aubert D, Balea A, Burrells A, Cherchi S, Cornelissen JBWJ, Dam-Deisz C, Guitian J, Györke A, Innes EA, Katzer F, Limon G, Possenti A, Pozio E, Schares G, Villena I, Wisselink HJ, van der Giessen JWB (2019) The relationship between the presence of antibodies and direct detection of Toxoplasma gondii in slaughtered calves and cattle in four European countries. Int J Parasitol 49(7):515–522

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Paululat A, Purschke G (2011) Toxoplasma. In: Paululat A, Purschke G (Hrsg) Wörterbuch der Zoologie, 8. Aufl. Spektrum Akademischer Verlag, Osnabrück, S 461

    Chapter  Google Scholar 

  49. 49.

    Pearson RD (2019) Toxoplasmose. Zugegriffen: 10. Juni 2021

  50. 50.

    Pleyer U, Gross U, Schlüter D, Wilking H, Seeber F (2019) Toxoplasmosis in Germany—epidemiology, diagnosis, risk factors, and treatment. Dtsch Arztebl Int 116:435–444

    PubMed  PubMed Central  Google Scholar 

  51. 51.

    Ramakrishnan C, Maier S, Walker RA, Rehrauer H, Joekel DE, Winiger RR, Basso WU, Grigg ME, Hehl AB, Deplazes P, Smith NC (2019) An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats. Sci Rep 9:1474

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  52. 52.

    Robert Koch-Institut (2018) Toxoplasmose: RKI-Ratgeber. Zugegriffen: 20. Aug. 2021

  53. 53.

    Sonaimuthu P, Ching XT, Fong MY, Kalyanasundaram R, Lau YL (2016) Induction of protective immunity against Toxoplasmosis in BALB/c mice vaccinated with Toxoplasma gondii Rhoptry‑1. Front Microbiol 7:808

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Speare R, Beveridge I, Johnson PM, Corner LA (1983) Parasites of the agile wallaby, macropus agilis (Marsupialia). Aust Wildl Res 10:89–96

    Article  Google Scholar 

  55. 55.

    Splendore A (1908) Un nuovo protozoa parassita deconigli incontrato nelle lesioni anatomiche d’une malattia che ricorda in molti punti il Kala-azar dell’uoma. Nota preliminare pel. Rev Soc Sci Sao Paulo 3:109–112

    Google Scholar 

  56. 56.

    Storch V, Welsch U (2014) Protozoa, Einzellige Tiere III: Apicomplexa (=Sporozoa i.e.s.). In: Storch V, Welsch U (Hrsg) Kükenthal: Zoologisches Praktikum, 27. Aufl. Springer Spektrum, Wiesbaden, S 28–35

    Google Scholar 

  57. 57.

    auf der Straße U (2019) Die Symptome einer aktiven Toxoplasmose. In: auf der Straße U (Hrsg) Das Toxoplasmose Handbuch: Ein Parasit täuscht die Medizin und macht uns krank – die aktive Toxoplasmose erkennen und behandeln, 2. Aufl. BoD – Books on Demand, Norderstedt, S 46–49

    Google Scholar 

  58. 58.

    Suzuki Y, Wang X, Jortner BS, Payne L, Ni Y, Michie SA, Xu B, Kudo T, Perkins S (2010) Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol 176(4):1607–1613

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Teimouri A, Azami SJ, Keshvaraz H, Esmaeili F, Alimi R, Mavi SA, Shojaee S (2018) Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomed 13:1341–1351

    CAS  Article  Google Scholar 

  60. 60.

    Tenter AM, Heckeroth AR, Weiss LM (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol 30:1217–1258

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Torun N, Sherif Z, Garweg J, Pleyer U (2008) Diagnostik und Behandlung der okulären Toxoplasmose – Eine Bestandsaufnahme unter deutschsprachigen Ophthalmologen. Ophthalmologe 105(11):1023–1028

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Vartak A, Sucheck SJ (2016) Recent advances in subunit vaccine carriers. Vaccines 4:12

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  63. 63.

    Wallon M, Peyron F (2018) Congenital Toxoplasmosis: a plea for a neglected disease. Pathogens 7:25

    PubMed Central  Article  PubMed  Google Scholar 

  64. 64.

    Wang JL, Li TT, Elsheikha HM, Chen K, Cong W, Yang WB, Bai MJ, Huang SY, Zhu XQ (2018) Live attenuated Pru:Δcdpk2 strain of Toxoplasma gondii protects against acute, chronic, and congenital toxoplasmosis. J Infect Dis 218:768–777

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Wang JL, Elsheikha HM, Zhu WN, Chen K, Li TT, Yue DM, Zhang XX, Huang SY, Zhu XQ (2017) Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice. Front Immunol 8:730

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  66. 66.

    Wang L, Tang D, Yang C, Yang J, Fang R (2020) Toxoplasma gondii ADSL knockout provides excellent immune protection against a variety of strains. Vaccines 8:16

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  67. 67.

    Yang WB, Wang JL, Gui Q, Zou Y, Chen K, Liu Q, Liang QL, Zhu XQ, Zhou DH (2019) Immunization with a live-attenuated RH:ΔNPT1 strain of Toxoplasma gondii induces strong protective immunity against toxoplasmosis in mice. Front Microbiol 10:1875

    PubMed  PubMed Central  Article  Google Scholar 

  68. 68.

    Yang J, Yang C, Qian J, Li F, Zhao J, Fang R (2020) Toxoplasma gondii α‑amylase deletion mutant is a promising vaccine against acute and chronic toxoplasmosis. Microb Biotechnol 13:2057–2069

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Yu Z, Zhou T, Luo Y, Dong L, Li C, Liu J, Luo J, Yan R, Xu L, Song X, Li X (2020) Modulation effects of Toxoplasma gondii histone H2A1 on murine macrophages and encapsulation with polymer as a vaccine candidate. Vaccines 8:731

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  70. 70.

    Zylka-Menhorn V (2013) Toxoplasmose-Test: Argumente für ein Screening. Dtsch Arztebl 110(10):A-446/B-399/C-399

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Yannick Borkens MPHTM.

Ethics declarations


Y. Borkens gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information


QR-Code scannen & Beitrag online lesen


M. Wehling, Mannheim

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Borkens, Y. Toxoplasma gondii – gegenwärtige Arzneimittel und zukünftige Impfstoffe gegen eine unterschätzte Protozoonose. Internist 62, 1123–1132 (2021).

Download citation


  • Lebensmittelerkrankungen
  • One Health
  • Parasiten
  • Toxoplasma-gondii-Impfungen
  • Toxoplasmose


  • Foodborne diseases
  • One Health
  • Parasites
  • Toxoplasmosis
  • Vaccines/Toxoplasma gondii